Botulinum Toxin in Restless Legs Syndrome-A Randomized Double-Blind Placebo-Controlled Crossover Study.

[BACKGROUND] Restless Legs Syndrome (RLS) is a common movement disorder with an estimated prevalence of up to 12%. Previous small studies with onabotulinumtoxin A (OnaA) for RLS have shown inconsistent results.

[METHODS] Twenty-four patients with an International RLS score (IRLS) of >11 (moderate-severe) were enrolled in this blinded, placebo-controlled crossover study. Twenty-one patients completed the evaluations at 4, 6, and 8 weeks after each injection. One-hundred units of Incobotulinumtoxin A (IncoA) or normal saline were injected into tibialis anterior, gastrocnemius, and biceps femoris muscles each side.

[RESULTS] Improvement from a severe (IRLS >21) to a mild/moderate (IRLS ≤20) score was significant at four weeks ( = 0.0036) and six weeks ( = 0.0325) following IncoA administration compared to placebo. Additionally, there was significant improvement in pain score at six weeks as measured by Visual Analogue Scale ( = 0.04) and the Johns Hopkins Quality of Life Questionnaire ( = 0.01) in the IncoA group. Definite or marked improvement on Patient Global Impression of Change was seen in 7 out of 21 patients in the IncoA group vs. 1 out of 21 patients in the placebo group at 4 weeks ( = 0.012).

[CONCLUSION] IncoA injection lead to a reduction in severity of RLS symptoms, pain score, and quality of life, without any adverse effects.